Overexpression of p75NTR in Testicular Germ Cell Tumors: a New Biomarker of Cancer Differentiation?

Anna Perri 1‡, Vittoria Rago 2‡, Rocco Malivindi 2, Lorenza Maltese 3, Danilo Lofaro 1, Emanuela Alessandra Greco 4, Luigi Tucci 3, Renzo Bonofiglio 1, Margherita Vergine 5, Sandro La Vignera 6, Eusebio Chiefari 4, Antonio Brunetti 4 and Antonio Aversa 5,*

Abstract: Several studies have demonstrated that the p75NTR low-affinity receptor of Nerve Growth Factor (NGF), is produced in abnormally large amounts in several human cancer types. However, the role of p75NTR varies substantially depending on cell context, so that a dual role of this receptor protein in tumor cell survival and invasion, as well as cell death, has been supported in recent studies. Herein we explored for the first time the expression of p75NTR in human specimens (n=40) from testicular germ cell tumors (TGCTs), mostly seminomas. Nuclear overexpression of p75NTR was detected by immunohistochemistry in tumor tissue as compared to normal tissue, whereas neither NGF nor its high-affinity TrkA receptor was detected. An increased nuclear staining of phospho-JNK, belonging to the p75NTR signaling pathway, and its pro-apoptotic target gene, p53, was concomitantly observed. Interestingly, our analysis revealed that decreased expression frequency of p75NTR, p-JNK, and p53 was related to staging progression, thus suggesting that p75NTR may represent a specific marker of differentiation in TGCTs.

Keywords: testicular germ cell tumors (TGCTs); human seminoma; p75 neurotrophin receptor (p75NTR); p75NTR-signaling.

1. Introduction

Testicular germ cell tumors (TGCTs) are the most common tumors in adolescent and young men, accounting for almost all testicular cancers, and their incidence is rising especially among Caucasians [1]. TGCTs are divided into seminomatous germ cell tumors (SGCT) and non-seminomatous germ cell tumors (NSGCT), the latter including undifferentiated (embryonal carcinoma) or differentiated (teratoma, yolk sac tumor, and chorionicarcinoma) tumors [2]. TGCTs have exceptional cure rates compared to other tumors, as 95% of affected men survive over 5 years [3]. Therefore, accurate staging and correct histopathological recognition of these tumors are critical for targeted therapy and optimal outcomes. Recent proteomic analysis of TGCTs identified novel proteins that might be used to better understand the molecular mechanism(s) involved in TGCTs [4]. As reported elsewhere [5], the histogenesis of TGCTs is complex, and it is thought that TGCTs might develop from premalignant intratubular germ cell neoplasia that progresses toward
invasive seminoma and/or nonseminoma after puberty, when cells start to proliferate under the influence of hormones [6]. It is believed that TGCTs may arise from the failure of normal maturation of gonocytes, although, to date, the exact molecular derangements underlying this transformation are not clearly understood, even if the most common genetic finding is the gain of genetic material from chromosome 12p [7]. Since mammalian spermatogenesis is an intricate sequential process of germ cell differentiation from primordial germ cells or spermatogonial stem cells to functional haploid sperm that occurs via a complex interaction between germ and somatic cells, a better knowledge of the regulatory control of spermatogenesis should provide crucial insights into the occurrence and features of TGCTs [8–11]. Studies in human and animal models have demonstrated that during testicular development, the neurotrophins, a family of polypeptide growth factors, and their receptors, are expressed in germ cells throughout their development and also in somatic cells, suggesting that the activation of their receptors may be important in testicular development and spermatogenesis [12–15].

Among neurotrophins, Nerve Growth Factor (NGF) and its high-affinity receptor, TrKA, before birth, exert an important role in seminiferous cord formation, germ cell differentiation, and Sertoli cell viability; after birth, they are involved in sperm motility and acrosome reaction. Fewer data are available on the potential function of the low-affinity NGF receptor p75NTR, a member of the tumor necrosis receptor superfamily, which seems to have important implications in early testicular development [16]. Interestingly, immunohistochemistry studies have demonstrated that NGF/TrkA/p75NTR are expressed in human breast, ovarian, and prostatic cancers, suggesting that they may represent new diagnostic markers. Concomitantly, in vitro and in vivo cancer models showed that NGF is involved in cancer cell progression, invasion, and chemoresistance, underlying that the NGF axis may represent a new therapeutic target in these tumors [17].

To our knowledge, there are no studies that have investigated the expression pattern of NGF/TrkA and p75NTR in testicular cancer. To better understand the potential implications relevant for the NGF signaling pathway in TGCTs, the objective of the current study was to explore the expression of NGF and its receptors particularly in human testicular seminoma, the most common histological type of TGCTs.

2. Results

2.1 Clinical characteristics of collected samples

Forty samples of primary TGCTs were collected. The median age of the 40 patients was 38 years (ranging from 25 to 51 years), and all patients were Caucasian.

More than half of the collected specimens presented with stage I neoplasms (67.5%) and the remaining were among stages II (17.5%), III (12.5%), and IV (2.5%), respectively. Seminoma was the most frequent histological type (65%), while embryonal carcinoma and mixed GCT were less represented (27.5% and 7.5%, respectively). Control testicular tissues were obtained from 4 male patients (aged 31 and 44 years), showing testes with a like-sarcoidosis granulomatous lesion.

2.2 Immunohistochemical of p75NTR, NGF and TrKA expression in TGCC

Immunohistochemical analysis revealed a strong nuclear immunoreactivity of p75NTR in the tumor sections compared to control tissue sections (Figure 1 G-H), whereas neither NGF nor TrKA staining was observed in the tumoral tissue (Figure 1 C-F).
The immunohistochemical expression (Table 1) was evaluated using the "Allred Score" (percent of positive cells) and intensity score (negative/weak/moderate/intense).

Table 1. Immunostaining scores (Allred score median) of NGF, TrkA, and p75NTR in seminoma samples. Immunostained slides scores as follows: Total score = Proposition score + Intensity score (range 0-8).

| Marker | Control | Seminoma |
|--------|---------|----------|
| NGF    | 3       | 0        |
| TrkA   | 2       | 0        |
| p75NTR | 4       | 8 §      |

§ p < 0.0001 (one-way ANOVA test) versus control.
Cutoffs for positivity of p75NTR marker were defined based on the area under the ROC curve, considering the sum of the score and the occurrence of clinical events (Table 2).

**Table 2.** p75NTR cutoff based on the area under the ROC curve.

| Marker   | Cutoff | Sensitivity (%) | Specificity (%) | PPV   | NPV   | AUC (95% CI) |
|----------|--------|----------------|-----------------|-------|-------|-------------|
| p75NTR   | ≥ 7    | 67.8%          | 59.0%           | 21.4% | 76.0% | 0.80 (0.75–0.98) |

AUC – Area under ROC curve; CI - Confidence interval; PPV – Positive predictive value; NPV – Negative predictive value

Concomitantly, we explored whether the observed overexpression of p75NTR was accompanied by a modulation of its downstream signaling JNK in seminoma tissue. Interestingly, in tumoral tissue, we found a decreased expression of total JNK (Figure 2 A-B; Table 3), with an increased expression of p-JNK as compared to control (Figure 2 C-D; Table 3).

![Figure 2](image_url) Immunolocalization of JNK (A, B) and p-JNK (C, D) in control testis and seminomas. Scale bars: 25 μm.

### 2.3 Immunohistochemical of p53 in TGCC

Immunohistochemical analysis revealed a strong nuclear immunoreactivity of p53 in the tumor sections compared to control tissue sections (Figure 3, Table 3).

**Table 3.** Immunostaining scores (Allred score median) of JNK, p-JNK, and p53 in human seminoma samples. Immunostained slides scores as follows: Total score= Proposition score+ Intensity score (range 0-8). * P<0.001 (one-way ANOVA test) versus control; **P<0.005 (one-way ANOVA test) versus control.

| Marker | Control | Seminoma |
|--------|---------|----------|
| JNK    | 6       | 4**      |
| p-JNK  | 5       | 6*       |
| P53    | 2       | 7**      |
2.4 Validation of TMA method

Analysis of agreement between TMA and whole tissue sections showed an accuracy for TMA method of 80% for NGF, 98% for TrkA, and 78% for p75NTR.

2.5 Clinico-pathological significance of p75NTR, p-JNK, and p53.

Interestingly, our analysis revealed that when compared to control tissue samples, all the proteins showed higher expression in samples with T1 tumor stage (p < 0.001) (Figure 4, Table 4).

| T stage | nr | NGF Positive (%) | p | TrkA Positive (%) | p | p75NTR Positive (%) | p |
|---------|----|------------------|---|-------------------|---|---------------------|---|
| T1      | 27 | 1 (0.03)         |   | 5 (5.9)           |   | 21 (77.7)           |   |
| T2      | 7  | 0 (0.0)          |   | 0 (0.0)           |   | 2 (28.5)            |   |
| T3      | 5  | 0 (0.0)          |   | 0 (0.0)           |   | 1 (20.0)            |   |
| T4      | 1  | 0 (0.0)          |   | 0 (0.0)           |   | 0 (0.0)             |   |
3. Discussion

As far as we are aware, this study represents the first description of the overexpression of p75NTR in TGCTs, particularly in testicular seminoma, and of its downstream signaling molecules, phospho-JNK and p53, whose expression decreases as tumor staging worsens. Different studies have proven that p75NTR plays opposite roles in the context of different cancers, as it acts as a tumor suppressor in carcinomas of prostate, bladder, stomach, and liver [18–20], whereas, in melanoma, pancreatic carcinoma, glioma, and breast cancer, p75NTR acts as a tumor-promoting function facilitating survival and invasion of cancer cells [21–23].

Although the involvement of p75NTR has been investigated in tumors affecting the female reproductive system, to our knowledge there are no studies that have explored the expression of p75NTR in TGCTs, in particular in testicular seminoma, which represents the most frequent testicular neoplasm in young men [1,24].

Previous studies have been carried out to identify new molecular markers for TGCTs. Preliminary reports demonstrated that most cells in seminoma express Pituitary-transforming-gene 1 (PTTG1) as well as Octamer-binding transcription factor 4 (OCT-4) and Krüppel-like factor 4 (KLF-4) [25]. The authors firstly demonstrated that PTTG1 marks some specific OCT4- and KLF4-positive tumor cells, mainly localized at the periphery of the neoplasm. In the intertubular infiltration areas, nests of cells expressing both OCT4/KLF4 and PTTG1 presence were consistent for a sub-population of tumor stem cells OCT4- and KLF4-positive [26]. In the present study, we aimed to investigate a new molecular pathway and found that the overexpression of p75NTR may have a pathogenetic role in testicular germ cell cancer development, which may occur in an NGF-independent manner [27,28], as confirmed by immunohistochemical Allred-score of negative NGF staining and its pro-survival receptor, TrkA, in tumoral tissue. Interestingly, Micera et al reported that the biological effect mediated by the NGF axis in both normal and cancer cells is related to the TrkA/p75NTR ratio and that the p75NTR expression might facilitate cell proliferation in the absence of TrkA [29].

We can speculate that p75NTR may be a biomarker of the transformed primordial germ cells, which represent the characteristic cellular pattern of testicular seminoma, in particular its pure forms [30]. The pathogenesis of overall TGTCs remains unexplored, although it is known that they originate from transformed gonocytes or undifferentiated spermatogonia [31]. Different observations using several malignancies refer to cells with a remarkable self-renewal potential and extensive proliferation capacity [32–34], expressing markers that characterize the stem cells of the original normal tissue [35] and that are strongly involved in growth and tumor propagation. A growing body of evidence has identified p75NTR as a robust cell surface biomarker for neural cancer-initiating or stem-like cells [36]. Interestingly, Okumura et al. demonstrated that in the stem/progenitor cell fraction of normal esophageal epithelial cells, p75NTR is necessary for tumor survival and maintenance [37]. Moreover, the in vivo study of Boiko et al. reported that melanoma tumor stem cells p75NTR-positive, but not p75NTR-negative, were remarkably capable of generating tumors, promoting metastasis, and maintaining self-renewal [38].

Furthermore, as expected, we observed that control testicular tissue expressed both total and phospho-JNK; and it has been reported that JNK is involved in regulating various testicular functions, like germ cell development and acrosome reactions, by controlling the expression of genes involved in the apoptosis or survival signaling pathways [39,40]. Concomitantly, we found that the overexpression of p75NTR in tumor tissue was

| Vascular invasion | ns | ns | 0.59 |
|-------------------|----|----|------|
| No                | 34 | 0 (0.0) | 0 (0.0) | 13 (38.2) |
| Yes               | 6  | 0 (0.0) | 0 (0.0) | 3 (64.3) |

| Histology | ns | ns | 0.0001 |
|-----------|----|----|--------|
| Seminoma  | 26 | 0 (0.0) | 0 (0.0) | 25 (96.1) |
| Non-seminomatous | 14 | 0 (0.0) | 0 (0.0) | 4 (28.5) |
accompanied by an increased nuclear expression of its downstream signaling, phospho-JNK. This result requires further investigation, as it has been extensively demonstrated that both p75NTR and JNK pathway activation can promote different biological effects, depending on cancer type [41]. Expression of p75NTR has been associated with apoptosis, through activation of JNK, which controls the expression of p53 tumor suppressor, and with cell survival, through the activation of nuclear factor-kB and AKT [42]. In addition to p75NTR and phospho-JNK overexpression, our analysis revealed a strong nuclear immunoreactivity of p53 in the tumor sections compared to control, highlighting that hyperactivation of p75NTR signaling in seminoma cells may promote cancer cell apoptosis. Furthermore, we hypothesized that p75NTR overexpression may represent a positive prognostic factor in seminoma, as we observed that p75NTR, phospho-JNK, and p53 expression frequency decreases with staging progression, suggesting that p75NTR could represent a marker of tumor differentiation. These results are in agreement with previous reports, demonstrating an inverse association of p75NTR expression with the neoplastic progression of prostate cancer [43,44].

Our study has some limitations. First of all, this is a retrospective study based on an archive of collected samples coming from testicular neoplasms, therefore, the lack of access to patients' clinical information limited the evaluation of any relationship between immunohistochemistry findings and tumor aggressiveness. Besides, we used the area under ROC curve to assess the cutoffs for p75NTR positivity and to investigate the definition of scores better associated with clinical events. Although it may vary depending on tumor type, we used this approach to estimate the possible clinical significance of p75NTR as a biomarker. TMA method demonstrated accuracy for all proteins analyzed. The tumor heterogeneity, quite common in TGCTs, could be a limitation of this method. However, in this study, scores in triplicate for each histological subtype were used, in the attempt to minimize this limitation. Lastly, the present study was not aimed to clarify any molecular pathway that could yield to any relevant functional mechanism(s) linked to tumor progression. Further studies are warranted.

4. Materials and Methods

4.1 Antibodies

The following primary antibodies were used: anti- p75NTR, anti-NGF, anti-TrkA, anti-p53 (Santa Cruz Biotechnology, Santa Cruz, CA), anti-JNK (phospho-JNK and total-JNK; Cell Signaling Technology, Milan, Italy).

Biotinylated goat-anti-rabbit, anti-mouse, anti-donkey IgGs were used as secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA).

4.2 Human tissues

All formalin-fixed and paraffin-embedded samples of TGCTs, stored from the 1st January 2015 to 31st December 2019 in the archives of the Division of Pathology, Hospital “A. Pugliese”, Catanzaro (Italy), were collected. Only samples from primary tumors before chemotherapy were selected. The clinicopathological data collected included age, date of diagnosis, histological type, tumor grade (when applicable), and the presence of vascular invasion.

At the time of orchidectomy, all patients gave their informed consent to use the remaining portions of tissue specimens for research purpose after their primary use for routine histologic staining. Therefore, for this study, no formal ethical approval was required for processing archival testicular tissue.

4.3 Tissue Microarray (TMA) construction and validation

All samples were analyzed, independently, by two pathological experts to confirm the diagnosis and delimitation of tumor areas for TMA cores. For each sample, both the tumor area and the corresponding normal tissues were selected (when available and sufficient) for triplicate cores of 1.0 mm. For TMA validation, 10 samples were randomly selected. For
these 10 samples, the immunohistochemical analysis was performed on both TMA and whole sections, and the results were compared.

4.4 Histopathological analysis

Morphological studies were carried out by Haematoxylin Eosin staining.

4.5 Immunohistochemistry

The immunohistochemical experiments were carried out on paraffin-embedded sections from all samples. Sections of 5 μm thick, after heat-mediated antigen retrieval, were obtained. Immunodetection was performed at 4 °C overnight, using the specific primary antibodies anti-NGF (1:100), anti-TrKA (1:100), anti- p75NTR (1:100), anti-p53(1:100), anti-JNK (1:100), and anti-posho-JNK (1:100). Then, biotinylated IgG (1:600) was applied for 1 hour at room temperature, followed by avidin-biotin complex (ABC)/horseradish peroxidase (HRP). Immunoreactivity was visualized by using diaminobenzidine chromogen (DAB). Sections were also counterstained with hematoxylin. The specificity of the Abs was verified by using normal rabbit serum and normal mouse serum, respectively, instead of the primary Abs. Immunostained slides of tumor samples were visualized using an Olympus BX41 microscope and the images were taken with CSV1.14 software, using a CAM XC-30 for image acquisition.

4.6 Scoring system

Immunoreactivity for human neoplastic tissues was scored using the "Allred Score" [45], which combines a proportion and an intensity score. A proportion score was assigned representing the estimated proportion of positively stained tumor cells on a scale from 0 to 5. An intensity score was assigned by the average estimated intensity of staining in positive cells on a scale from 0 to 3. Proportion score and intensity score were added to obtain a total score that ranged from 0 to 8. A minimum of 100 cells were evaluated in each slide. Six serial sections were scored for each sample.

4.7 Statistical Analysis

The results obtained with the human samples were analyzed using Prism GraphPad (version 9.0). ROC curve was used to define the final score cutoff for positivity, based on the area under the curve. The frequency of protein expression and comparison with clinicopathological data as well as the differences in the scores between seminoma and control samples were analyzed using the one-way ANOVA. The Wilcoxon test was used after ANOVA as post-hoc test. The agreement between TMA and whole sections was evaluated by the accuracy of the method.

5. Conclusions

In conclusion, our results suggest that p75NTR may exert a pathogenetic role in TGCTs and that the loss of its expression may represent a marker of worse tumoral differentiation. However, the mechanism(s) underlying the controversial and paradoxical functions of p75NTR in different cancer cells are not entirely explained. Further studies are needed to investigate the relevance of our findings, to establish whether p75NTR may be considered a new marker of differentiated TGCT and a potential pharmacological target for the treatment in selected cases of TGCTs.

Author Contributions: Conceptualization AP and A.A.; Methodology: V.R., R.M., L.M., E.A.G. and S.L.V.; software D.L. and M.V.; validation L.T. and R.B., A.P., E.A.G. and S.L.V; writing—original draft preparation, A.P and V.R.; review and editing, E.A.G., E.C., A.B. and A.A. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding

Conflicts of Interest: The authors declare no conflict of interest.
1. Ghazarian, A.A.; Kelly, S.P.; Altekruse, S.F.; Rosenberg, P.S.; McGlynn, K.A. Future of Testicular Germ Cell Tumor Incidence in the United States: Forecast through 2026. Cancer 2017, 123, 2320–2328.
2. Bode, P.K.; Thielken, A.; Brandt, S.; Barghorn, A.; Lobe, B.; Knuth, A.; Moch, H. Cancer Testis Antigen Expression in Testicular Germ Cell Tumorigenesis. Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc 2014, 27, 899–905.
3. Le Comtet, C.; Lortet-Tieulent, J.; Forman, D.; Béranger, R.; Flechon, A.; Fervers, B.; Schütz, J.; Bray, F. Testicular Cancer Incidence to Rise by 25% by 2025 in Europe? Model-Based Predictions in 40 Countries Using Population-Based Registry Data. Eur. J. Cancer Oxf. Engl. 1990 2014, 50, 831–839.
4. Milardi, D.; Grande, G.; Vincenzoni, F.; Pierconti, F.; Pontecorvi, A. Proteomics for the Identification of Biomarkers in Testicular Cancer-Review. Front. Endocrinol. 2019, 10, 462.
5. Batool, A.; Karimi, N.; Wu, X.-N.; Chen, S.-R.; Liu, Y.-X. Testicular Germ Cell Tumor: A Comprehensive Review. Cell. Mol. Life Sci. CMLS 2019, 76, 1713–1727.
6. Skakkebaek, N.E. Possible Carcinoma-in-Situ of the Testis. Lancet Lond. Engl. 1972, 2, 516–517.
7. Sheikine, Y.; Genega, E.; Melamed, J.; Lee, P.; Reuter, V.E.; Ye, H. Molecular Genetics of Testicular Germ Cell Tumors. Am. J. Cancer Res. 2012, 2, 153–167.
8. Chen, S.-R.; Liu, Y.-X. Regulation of Spermatogonial Stem Cell Self-Renewal and Spermatocyte Meiosis by Sertoli Cell Signaling. Reprod. Camb. Engl. 2015, 149, R159–167.
9. Chen, S.-R.; Zheng, Q.-S.; Zhang, Y.; Gao, F.; Liu, Y.-X. Disruption of Genital Ridge Development Causes Aberrant Primordial Germ Cell Proliferation but Does Not Affect Their Directional Migration. BMC Biol. 2013, 11, 22.
10. Reboucet, D.; O’Shaughnessy, P.J.; Pitetti, J.-L.; Monteiro, A.; O’Hara, L.; Milne, L.; Tsai, Y.T.; Cruickshanks, L.; Riethmacher, D.; Guillou, F.; et al. Sertoli Cells Control Peritubular Myoid Cell Fate and Support Adult Leydig Cell Development in the Prepubertal Testis. Dev. Camb. Engl. 2014, 141, 2139–2149.
11. Wang, Y.-Q.; Batool, A.; Chen, S.-R.; Liu, Y.-X. GATA4 Is a Negative Regulator of Contractility in Mouse Testicular Peritubular Myoid Cells. Reprod. Camb. Engl. 2018, 156, 343–351.
12. Persson, H.; Ayer-Le Lievre, C.; Söder, O.; Villar, M.J.; Metis, M.; Olson, L.; Ritzen, M.; Hökfelt, T. Expression of Beta-Nerve Growth Factor Receptor mRNA in Sertoli Cells Downregulated by Testosterone. Science 1990, 247, 704–707.
13. Müller, D.; Davidoff, M.S.; Bargheer, O.; Paust, H.-J.; Pusch, W.; Koewa, Y.; Jezek, D.; Holstein, A.F.; Middendorff, R. The Expression of Neurotrophins and Their Receptors in the Prenatal and Adult Human Testis: Evidence for Functions in Leydig Cells. Histoch. Cell Biol. 2006, 126, 199–211.
14. Russo, M.A.; Odorisio, T.; Fradeani, A.; Rienzi, L.; De Felici, M.; Cattaneo, A.; Siracusa, G. Low-Affinity Nerve Growth Factor Receptor Is Expressed during Testicular Morphogenesis and in Germ Cells at Specific Stages of Spermatogenesis. Mol. Reprod. Dev. 1994, 37, 157–166.
15. Djakiew, D.; Pflug, B.; Dionne, C.; Onoda, M. Postnatal Expression of Nerve Growth Factor Receptors in the Rat Testis. Biol. Reprod. 1994, 51, 214–221.
16. Li, C.; Zhou, X. The Potential Roles of Neurotrophins in Male Reproduction. Reprod. Camb. Engl. 2013, 145, R89–95.
17. Griffin, N.; Faulkner, S.; Jobling, P.; Hondermarck, H. Targeting Neurotrophin Signaling in Cancer: The Renaissance. Pharmacol. Res. 2018, 135, 12–17.
18. Jin, H.; Pan, Y.; He, L.; Zhai, H.; Li, X.; Zhao, L.; Sun, L.; Liu, J.; Hong, L.; Song, J.; et al. P75 Neurotrophin Receptor Inhibits Invasion and Metastasis of Gastric Cancer. Mol. Cancer Res. MCR 2007, 5, 423–433.
19. Khwaja, F.S.; Quann, E.J.; Pattabiraman, N.; Wynne, S.; Djakiew, D. Carprofen Induction of P75NTR-Dependent Apoptosis via the P38 Mitogen-Activated Protein Kinase Pathway in Prostate Cancer Cells. Mol. Cancer Ther. 2008, 7, 3539–3545.
20. Gravina, G.L.; Marampon, F.; Sanità, P.; Mancini, A.; Colapietro, A.; Scarsella, L.; Jitariuc, A.; Biordi, L.; Ficorella, C.; Festuccia, C. Increased Expression and Activity of P75NTR Are Crucial Events in Azacitidine-Induced Cell Death in Prostate Cancer. Oncol. Rep. 2016, 36, 125–130.
21. Marchetti, D.; Aucoin, R.; Blust, J.; Murry, B.; Greiter-Wilke, A. P75 Neurotrophin Receptor Functions as a Survival Receptor in Brain-Metastatic Melanoma Cells. J. Cell. Biochem. 2004, 91, 206–215.

22. Wang, L.; Rahn, J.J.; Lun, X.; Sun, B.; Kelly, J.J.P.; Weiss, S.; Robbins, S.M.; Forsyth, P.A.; Senger, D.L. Gamma-Secretase Represents a Therapeutic Target for the Treatment of Invasive Glioma Mediated by the P75 Neurotrophin Receptor. PLoS Biol. 2008, 6, e289.

23. Verbeke, S.; Tomellini, E.; Dhamani, F.; Meignan, S.; Adriaenssens, E.; Xuefen, L.B. Extracellular Cleavage of the P75 Neurotrophin Receptor Is Implicated in Its Pro-Survival Effect in Breast Cancer Cells. FEBS Lett. 2013, 587, 2591–2596.

24. Dieckmann, K.-P.; Richter-Simonsen, H.; Kulejewski, M.; Ikogho, R.; Zecha, H.; Anheuser, P.; Pichlmeyer, U.; Isbarn, H. Testicular Germ-Cell Tumours: A Descriptive Analysis of Clinical Characteristics at First Presentation. Urol. Int. 2018, 100, 409–419.

25. Pierconti, F.; Milardi, D.; Martini, M.; Grande, G.; Tenc, T.; Gulino, G.; Larocca, L.; Rindi, G.; Pontecorvi, A.; De Marinis, L. Pituitary-Tumour-Transforming-Gene 1 Expression in Testicular Cancer. Andrologia 2015, 47, 427–432.

26. Grande, G.; Milardi, D.; Martini, M.; Conci, T.; Gulino, G.; Mancini, F.; Bianchi, A.; Pontecorvi, A.; Pierconti, F. Protein Expression of PTTG-1, OCT-4, and KLF-4 in Seminoma: A Pilot Study. Front. Endocrinol. 2019, 10, 619.

27. Rabizadeh, S.; Oh, J.; Zhong, L.T.; Yang, J.; Bitler, C.M.; Butcher, L.L.; Brederesen, D.E. Induction of Apoptosis by the Low-Affinity NGF Receptor. Science 1993, 261, 345–348.

28. Gentry, J.J.; Casaccia-Bonnefil, P.; Carter, B.D. Nerve Growth Factor Activation of Nuclear Factor kappaB through Its P75 Receptor Is an Anti-Apoptotic Signal in RN22 Schwannoma Cells. J. Biol. Chem. 2000, 275, 7558–7565.

29. Micera, A.; Lambiase, A.; Stampachiaciere, B.; Bonini, S.; Bonini, S.; Levi-Schaffer, F. Nerve Growth Factor and Tissue Repair Remodeling: TrkA(NGFR) and P75(NTR), Two Receptors One Fate. Cytokine Growth Factor Rev. 2007, 18, 245–256.

30. Spenger, J.M.; Chen, X.; Draper, J.S.; Antosiewicz, J.E.; Chon, C.H.; Jones, S.B.; Brooks, J.D.; Andrews, P.W.; Brown, P.O.; Thomson, J.A. Gene Expression Patterns in Human Embryonic Stem Cells and Human Pluripotent Germ Cell Tumours: A Descriptive Analysis of Clinical Characteristics at First Presentation. Hum. Reprod. Update 2003, 100, 13350–13355.

31. Rajpert-De Meyts, E. Developmental Model for the Pathogenesis of Testicular Carcinoma in Situ: Genetic and Environmental Aspects. Hum. Reprod. Update 2006, 12, 303–323.

32. Al-Hajj, M.; Wicha, M.S.; Benito-Hernandez, A.; Morrison, S.J.; Clarke, M.F. Prospective Identification of Tumorigenic Breast Cancer Cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 3983–3988.

33. Singh, S.K.; Hawkins, C.; Clarke, I.D.; Squire, J.A.; Bayani, J.; Hide, T.; Henkelman, R.M.; Cusimano, M.D.; Dirks, P.B. Identification of Human Brain Tumour Initiating Cells. Nature 2004, 432, 396–401.

34. Hemmati, H.D.; Nakano, I.; Lazareff, J.A.; Masterman-Smith, M.; Geschwind, D.H.; Bronner-Fraser, M.; Kornblum, H.I. Cancerous Stem Cells Can Arise from Pediatric Brain Tumors. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 15178–15183.

35. Dean, M.; Fojo, T.; Bates, S. Tumour Stem Cells and Drug Resistance. Nat. Rev. Cancer 2005, 5, 275–284.

36. Tomellini, E.; Lagadec, C.; Polakowska, R.; Le Bourhis, X. Role of P75 Neurotrophin Receptor in Stem Cell Biology: More than Just a Marker. Cell. Mol. Life Sci. CMLS 2014, 71, 2467–2481.

37. Okumura, T.; Tsunoda, S.; Mori, Y.; Ito, T.; Kikuchi, K.; Wang, T.C.; Yasumoto, S.; Shimada, Y. The Biological Role of the Low-Affinity P75 Neurotrophin Receptor in Esophageal Squamous Cell Carcinoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2006, 12, 5096–5103.

38. Boiko, A.D.; Razorenova, O.V.; van de Rijn, M.; Swetter, S.M.; Johnson, D.L.; Ly, D.P.; Butler, P.D.; Yang, G.P.; Joshua, B.; Kaplan, M.J.; et al. Human Melanoma-Initiating Cells Express Neural Crest Nerve Growth Factor Receptor CD271. Nature 2010, 466, 133–137.

39. Herrera, S.C.; Bach, E.A. JNK Signaling Triggers Spermatogonial Dedifferentiation during Chronic Stress to Maintain the Germline Stem Cell Pool in the Drosophila Testis. eLife 2018, 7.

40. Kyriakis, J.M.; Banerjee, P.; Nikolakaki, E.; Dai, T.; Rubie, E.A.; Ahmad, M.F.; Avrch, J.; Woodgett, J.R. The Stress-Activated Protein Kinase Subfamily of c-Jun Kinases. Nature 1994, 369, 156–160.

41. Bubici, C.; Papa, S. JNK Signalling in Cancer: In Need of New, Smarter Therapeutic Targets. Br. J. Pharmacol. 2014, 171, 24–37.
42. Roux, P.P.; Bhakar, A.L.; Kennedy, T.E.; Barker, P.A. The P75 Neurotrophin Receptor Activates Akt (Protein Kinase B) through a Phosphatidylinositol 3-Kinase-Dependent Pathway. *J. Biol. Chem.* **2001**, *276*, 23097–23104.

43. Pflug, B.R.; Onoda, M.; Lynch, J.H.; Djakiew, D. Reduced Expression of the Low Affinity Nerve Growth Factor Receptor in Benign and Malignant Human Prostate Tissue and Loss of Expression in Four Human Metastatic Prostate Tumor Cell Lines. *Cancer Res.* **1992**, *52*, 5403–5406.

44. Krygier, S.; Djakiew, D. Neurotrophin Receptor P75(NTR) Suppresses Growth and Nerve Growth Factor-Mediated Metastasis of Human Prostate Cancer Cells. *Int. J. Cancer* **2002**, *98*, 1–7.

45. Allred, D.C.; Harvey, J.M.; Berardo, M.; Clark, G.M. Prognostic and Predictive Factors in Breast Cancer by Immunohistochemical Analysis. *Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc* **1998**, *11*, 155–168.